West Pharmaceutical Services (WST) Cash & Equivalents (2009 - 2026)

West Pharmaceutical Services has reported Cash & Equivalents for 18 years, with the latest figure at $435.8 million in Q2 2026.

• Quarterly Cash & Equivalents fell 14.5% year-over-year to $435.8 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $435.8 million (down 14.5% YoY) and the FY2025 annual result came in at $791.3 million, up 63.29% from the prior year.
• Cash & Equivalents declined to $435.8 million in Q2 2026 per WST's latest filing, from $521.4 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $898.6 million in Q3 2023 and troughed at $404.2 million in Q1 2025.
• A 5-year average of $653.3 million and a median of $648.1 million in 2022 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2024 and 2025: Cash & Equivalents plunged 45.37% in 2024, then soared 63.29% in 2025.
• Over 5 years, Cash & Equivalents stood at $894.3 million in 2022, then decreased by 4.52% to $853.9 million in 2023, then slumped by 43.25% to $484.6 million in 2024, then jumped by 63.29% to $791.3 million in 2025, then sank by 44.93% to $435.8 million in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $435.8 million, $521.4 million, and $791.3 million for Q2 2026, Q1 2026, and Q4 2025 respectively.